A Study to Learn About a Vaccine Against E Coli in Healthy Adults
← catalyst calendarNCT07122986 · readout in 646 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
310estimated
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-11 | actual | When the study began enrolling |
| Primary completion | 2028-05-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: E coli vaccine 1 Dose A
- Drug: E coli vaccine 1 Dose B
- Drug: E coli vaccine 2
- Drug: E coli vaccine 3
- Drug: E coli Vaccine 4 Dose A
- Drug: E coli Vaccine 4 Dose B
- Drug: E coli Vaccine 4 Dose C
- Drug: E coli Vaccine 5 Dose A
- Drug: E coli Vaccine 5 Dose B
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting prespecified local events within 7 days following each vaccination
measured 7 days after each vaccination
Percentage of participants reporting prespecified systemic events within 7 days following each vaccination
measured 7 days after each vaccination
Percentage of participants reporting Adverse Events (AEs) from vaccination 1 through 1 month after the last dose of study intervention
measured From signing of ICD to 1 month after the last assigned vaccination
Percentage of participants reporting Medically Attended Adverse Events (MAEs) from vaccination 1 through 12 months after the last dose of study intervention
measured Baseline up to month 18 with final visit being 12 months after last assigned vaccination
Percentage of participants reporting Serious Adverse Events (SAEs) from vaccination 1 through 12 months after the last dose of study intervention
measured Baseline up to month 18 with final visit being 12 months after last assigned vaccination
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed